Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Debra Brent

Nurse Practitioner, Acute Care Little Rock, AR Nurse Practitioner

NPI 1518923903 CMS profile 10420685

800 Fair Park Blvd, Little Rock, AR 72204

Open in the dashboard

General payments

$8,763

478 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Debra Brent of Little Rock, AR is reported in the CMS Open Payments database as having received $8,763 across 478 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,070 75
2024 General $1,151 66
2023 General $2,403 118
2022 General $2,494 122
2021 General $1,645 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Debra Brent
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Debra Brent were reported at $1,070. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Debra Brent Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,645 $123 $38–$327 $132
2022 $2,494 $130 $44–$369 $149
2023 $2,403 $144 $49–$410 $160
2024 $1,151 $146 $48–$433 $164
2025 $1,070 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,638 159 payments
  2. Amgen Inc. $1,677 111 payments
  3. UCB, Inc. $904 38 payments
  4. Janssen Biotech, Inc. $749 41 payments
  5. Mallinckrodt Hospital Products Inc. $334 12 payments
  6. Pfizer Inc. $301 16 payments
  7. Aurinia Pharma U.S., Inc. $244 11 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $227 11 payments
  9. Genentech USA, Inc. $222 13 payments
  10. AstraZeneca Pharmaceuticals LP $195 11 payments
  11. Other $1,272 55 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,642 473 payments
  2. Education $121 5 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $2,045 118 payments
  2. SIMPONI ARIA $749 41 payments
  3. Otezla $604 52 payments
  4. Cimzia $580 28 payments
  5. Enbrel Inflammation $577 47 payments
  6. EVENITY $515 28 payments
  7. SKYRIZI $472 29 payments
  8. TREMFYA $465 17 payments
  9. Enbrel Inflammation $395 24 payments
  10. Prolia $338 22 payments
  11. Other $4,754 242 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

5,769

Median for Nurse Practitioner: 389

Drug cost

$1,116,677

Median for Nurse Practitioner: $21,885

Branded share of claims

18.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 40 $295,853
Rinvoq Upadacitinib Brand 35 $223,815
Otezla Apremilast Brand 29 $125,512
Xeljanz Xr Tofacitinib Citrate Brand 18 $102,301
Enbrel Sureclick Etanercept Brand 11 $77,823
Orencia Clickject Abatacept Brand 12 $67,665
Kevzara Sarilumab Brand 13 $55,553
Hydroxychloroquine Sulfate Generic 1,083 $47,566
Colchicine Generic 217 $21,651
Leflunomide Generic 247 $14,675

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 85 billing codes

Paid by Medicare

$810,246

Of which drugs: $693,878

Medicare patients

458

Average age 71

Services billed

70,682

345 women, 113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 38%
Depression 34%
Ischemic heart disease 33%
Chronic kidney disease 23%
Diabetes 21%
COPD 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, tocilizumab, 1 mg J3262 Office 11 18,167 $85,459
Injection, romosozumab-aqqg, 1 mg J3111 Office 11 8,190 $70,848
Injection, denosumab, 1 mg J0897 Office 44 3,300 $67,840
Injection, golimumab, 1 mg, for intravenous use J1602 Office 19 7,900 $67,242
Injection, infliximab-abda, biosimilar, (renflexis), 10 mg Q5104 Office 21 2,072 $46,103
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 14 1,789 $43,669
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 54 300 $1,629
Injection, methylprednisolone acetate, 1 mg J1010 Office 55 9,684 $980
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 24 1,456 $330
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 144 $71

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$304 35 —
Enbrel
$166 11 —
Otezla
$78 29 —
SKYRIZI
$65 — —
EVENITY
$62 — 8,190

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

478 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Acute Care in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record